446 related articles for article (PubMed ID: 3510720)
41. Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates.
Colombatti M; Colombatti A; Blythman HE; Bron C
J Natl Cancer Inst; 1984 May; 72(5):1095-9. PubMed ID: 6585586
[TBL] [Abstract][Full Text] [Related]
42. Elimination of small cell lung cancer cells in vitro from human bone marrow by a monoclonal antibody.
Okabe T; Kaizu T; Ozawa K; Urabe A; Takaku F
Cancer Res; 1985 May; 45(5):1930-3. PubMed ID: 2985239
[TBL] [Abstract][Full Text] [Related]
43. In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody.
Dinota A; Tazzari PL; Michieli M; Visani G; Gobbi M; Bontadini A; Tassi C; Fanin R; Damiani D; Grandi M
Cancer Res; 1990 Jul; 50(14):4291-4. PubMed ID: 1694719
[TBL] [Abstract][Full Text] [Related]
44. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
[TBL] [Abstract][Full Text] [Related]
45. Photoradiation methods for purging autologous bone marrow grafts.
Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
[TBL] [Abstract][Full Text] [Related]
46. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Embleton MJ; Byers VS; Lee HM; Scannon P; Blackhall NW; Baldwin RW
Cancer Res; 1986 Nov; 46(11):5524-8. PubMed ID: 3489523
[TBL] [Abstract][Full Text] [Related]
48. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow.
Myklebust AT; Godal A; Juell S; Pharo A; Fodstad O
Cancer Res; 1994 Jan; 54(1):209-14. PubMed ID: 7505198
[TBL] [Abstract][Full Text] [Related]
49. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow.
Quinones RR; Youle RJ; Kersey JH; Zanjani ED; Azemove SM; Soderling CC; Lebien TW; Beverley PC; Neville DM; Vallera DA
J Immunol; 1984 Feb; 132(2):678-83. PubMed ID: 6606676
[TBL] [Abstract][Full Text] [Related]
50. Effects of ricin A chain conjugates of monoclonal antibodies to human alpha-fetoprotein and placental alkaline phosphatase on antigen-producing tumor cells in culture.
Tsukazaki K; Hayman EG; Ruoslahti E
Cancer Res; 1985 Apr; 45(4):1834-8. PubMed ID: 2579736
[TBL] [Abstract][Full Text] [Related]
51. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
Miller G; Brashear T; Stone M; Fay J
Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
[TBL] [Abstract][Full Text] [Related]
52. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
53. Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia.
Delwel R; Bot F; Knapp W; Löwenberg B
Bone Marrow Transplant; 1987 Aug; 2(2):149-54. PubMed ID: 3332163
[TBL] [Abstract][Full Text] [Related]
54. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
55. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
56. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
57. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
58. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
59. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
60. [Selective cytotoxicity of an antibody-ricin A chain conjugate for human tumor cells].
Tonevitskiĭ AG
Mol Biol (Mosk); 1985; 19(4):1034-41. PubMed ID: 4047033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
